XML 41 R8.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Cash flows from operating activities:      
Net income $ 1,503 $ 1,848 $ 273
Adjustments to reconcile net income to net cash provided by operating activities:      
Deferred income taxes (352) (35) (181)
Provision for inventories 6 6 33
Non-cash operating lease cost 64 0 0
Depreciation and amortization 328 509 888
Amortization of capitalized software development costs and intellectual property licenses [1] 225 489 311
Loss on extinguishment of debt 0 40 12
Share-based compensation expense [2] 166 209 176
Unrealized gain on equity investment (38) 0 0
Other 51 7 40
Changes in operating assets and liabilities, net of effect from business acquisitions:      
Accounts receivable, net 182 (114) (165)
Inventories 7 (5) (26)
Software development and intellectual property licenses (275) (372) (301)
Other assets 164 (51) (97)
Deferred revenues (154) (122) 220
Accounts payable 31 (65) 85
Accrued expenses and other liabilities (77) (554) 945
Net cash provided by operating activities 1,831 1,790 2,213
Cash flows from investing activities:      
Proceeds from maturities of available-for-sale investments 153 116 80
Purchases of available-for-sale investments (65) (209) (135)
Capital expenditures (116) (131) (155)
Other investing activities 6 (6) 3
Net cash used in investing activities (22) (230) (207)
Cash flows from financing activities:      
Proceeds from issuance of common stock to employees 105 99 178
Tax payment related to net share settlements on restricted stock units (59) (94) (56)
Dividends paid (283) (259) (226)
Proceeds from debt issuances, net of discounts 0 0 3,741
Repayment of long-term debt 0 (1,740) (4,251)
Premium payment for early redemption of note 0 (25) 0
Other financing activities 0 (1) (10)
Net cash used in financing activities (237) (2,020) (624)
Effect of foreign exchange rate changes on cash and cash equivalents (3) (31) 76
Net increase (decrease) in cash and cash equivalents and restricted cash 1,569 (491) 1,458
Cash and cash equivalents and restricted cash at beginning of period 4,229 4,720 3,262
Cash and cash equivalents and restricted cash at end of period $ 5,798 $ 4,229 $ 4,720
[1]
Excludes deferral and amortization of share-based compensation expense.
[2]
Includes the net effects of capitalization, deferral, and amortization of share-based compensation expense.